As the first anti-angiogenesis monoclonal antibody, bevacizumab has been an vital component of front line regimen of advanced nonsqaumous non-small cell lung cancer (NSCLC). It increase the efficacy of chemotherapy, epithelial growth factor receptor tyrosine kinase inhibitors and immune checkpoint inhibitors. This article is an important review of existing randomized controlled clinical research, hoping to provide a reference for clinical treatment. The addition of bevacizumab reduces the risk of disease progression in patients with advanced non-squamous NSCLC significantly. Specific combinations can also reduce the risk of death. The best combination plan needs to be confirmed by new randomized controlled studies.
【中文题目：贝伐珠单抗在晚期非小细胞肺癌一线治疗中的研究进展】 【中文摘要：贝伐珠单抗作为首个抗血管新生的单克隆抗体已经成为晚期非鳞非小细胞肺癌（non-small cell lung cancer, NSCLC）一线治疗的重要组成部分，与化疗、分子靶向治疗以及免疫检查点抑制剂联合使用增强了这些药物的抗肿瘤作用，本文对已有的随机对照临床研究进行综述，希望能为临床治疗工作提供参考。贝伐珠单抗的加入可以显著降低晚期非鳞NSCLC患者的疾病进展风险，特定组合还可以降低患者的死亡风险，最佳组合方案还有待于新的随机对照研究证实。】 【中文关键词：贝伐珠单抗；肺肿瘤；一线治疗】.
Keywords: Bevacizumab; Front line treatment; Lung neoplasms.